{"id":"bp-scig-20","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This subcutaneous immunoglobulin (SCIg) formulation at 20% concentration replaces deficient or dysfunctional IgG antibodies in patients unable to produce adequate endogenous immunoglobulin. The therapy is administered subcutaneously, allowing for more frequent dosing intervals and improved quality of life compared to intravenous immunoglobulin (IVIg), while maintaining systemic IgG levels to prevent recurrent infections.","oneSentence":"BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:52.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders requiring immunoglobulin replacement"}]},"trialDetails":[{"nctId":"NCT07346859","phase":"PHASE3","title":"Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)","status":"RECRUITING","sponsor":"Biopharma Plasma LLC","startDate":"2025-12-17","conditions":"Primary Immunodeficiency Diseases","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2524090,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BP-SCIG 20%","genericName":"BP-SCIG 20%","companyName":"Biopharma Plasma LLC","companyId":"biopharma-plasma-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}